title: Reply to A.-S. Dieudonné et al and J.M. Rae et al.
authors.forename: Hiltrud
authors.initials: H
authors.lastname: Brauch
authors.forename: Werner
authors.initials: W
authors.lastname: Schroth
authors.forename: Matthew P
authors.initials: MP
authors.lastname: Goetz
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Mürdter
authors.forename: Stefan
authors.initials: S
authors.lastname: Winter
authors.forename: James N
authors.initials: JN
authors.lastname: Ingle
authors.forename: Matthias
authors.initials: M
authors.lastname: Schwab
authors.forename: Michel
authors.initials: M
authors.lastname: Eichelbaum
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D005260:Female; D006801:Humans; D017698:Postmenopause / Q000235:genetics*; D013629:Tamoxifen / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; D019389:Cytochrome P-450 CYP2D6